# ZoomRx

> ZoomRx is a privately held life-sciences consultancy and software company that combines primary research, commercial analytics, proprietary healthcare-professional and patient panels, and purpose-built AI. Its bet is that pharma insight work should compound: Sagan Agents makes old and new customer research queryable, Ferma monitors competitive and conference intelligence, and consultants turn the resulting evidence into launch, brand, medical-affairs, and sales decisions.

- **Founded:** 2009
- **Headquarters:** Cambridge, United States
- **Founders:** Sriram Subramanian (Co-Founder and Co-CEO), Karthik Kalyanam (Co-Founder and Co-CEO)
- **Team size:** Approximately 550 employees in the supplied record; ZoomRx publicly reports 450+ life-sciences consultants worldwide, while LinkedIn lists roughly 544 employees.
- **Products:** Strategic market research consulting, Promotional Effectiveness Tracking (PET), Awareness, Trial & Usage (ATU), Patient Scribe and Patient Chart Audits, HCP-Patient Conversations
- **Notable:** Founded in 2009 and built a specialist life-sciences business operating across the United States and India., Company-reported customer reach of 100+ biopharma companies, including 19 of the top 20 global biopharma companies., Built a proprietary panel of 60,000+ healthcare professionals and patients and a benchmark base of 700M+ data points, according to ZoomRx.

## Products & services

- **Strategic market research consulting** — Primary research, launch strategy, customer insights and therapeutic-area consulting for pharmaceutical and biotechnology companies.
- **Promotional Effectiveness Tracking (PET)** — Tracks HCP message recall after sales interactions and links field execution with prescription outcomes and benchmarks.
- **Awareness, Trial & Usage (ATU)** — Global brand tracking for awareness, trial intent, usage, barriers and competitive positioning, with conversational and dashboard components.
- **Patient Scribe and Patient Chart Audits** — Voice-first chart collection and analysis intended to capture clinical reasoning with less form-entry burden for participating HCPs.
- **HCP-Patient Conversations** — Consented, de-identified research based on real clinical conversations, analyzed to explain treatment decisions that claims data cannot.
- **Brand Builder** — An integrated qualitative, quantitative and strategic planning program inherited through the Vivisum Partners acquisition, spanning early clinical development through launch.
- **Ferma** — AI market-intelligence platform comprising Ferma Congress for conference coverage and Ferma Agents for pipeline, competitive and business-development workflows.
- **Sagan** — AI-enhanced pharma market-research platform combining natural conversations, real HCP and patient panels, simulations and search.
- **Sagan Agents** — Continuous-intelligence platform that connects customer research archives, market data and agentic research workflows with traceable evidence.
- **Decision Sciences** — Commercial analytics spanning forecasting, segmentation, claims and prescription analysis, sales-force optimization and promotional mix.
- **Signal-IQ** — Competitive field-intelligence offering that turns de-identified mobility signals into weekly or biweekly estimates of competitor sales activity around HCP targets.

## Achievements

- Founded in 2009 and built a specialist life-sciences business operating across the United States and India.
- Company-reported customer reach of 100+ biopharma companies, including 19 of the top 20 global biopharma companies.
- Built a proprietary panel of 60,000+ healthcare professionals and patients and a benchmark base of 700M+ data points, according to ZoomRx.
- Ferma was selected for PM360's 2023 Innovations Issue in the artificial-intelligence category; PM360 said early users reported 50% to 75% time savings per medical response document.
- Acquired Vivisum Partners in January 2024, adding Brand Builder and deeper pre-launch qualitative research capabilities.
- Expanded Ferma Congress to company-reported coverage of 250+ global conferences across nine therapeutic areas since 2020.
- Launched Sagan in June 2025, Sagan Agents in May 2026 and Signal-IQ in July 2026.
- ZoomRx reports a 99.8% sample-fulfillment rate for its proprietary panel.
- ZoomRx reports that 2026 Signal-IQ backtests matched client call files at rates above 85% for tested brands.

## Latest updates

- **2026-08** — Published new research on psoriasis treatment conversations and guidance on AI governance and evidence trails.
- **2026-07** — Launched Signal-IQ for near-real-time, NPI-level estimates of competitor pharma sales-force activity; also detailed Sagan's agent orchestration and agentic research workflows.
- **2026-05** — Launched Sagan Agents as an enterprise operating system for customer-insights workflows, with research archives, agentic market research and evidence trails.
- **2026-03** — Published an Arcutis Biotherapeutics case study on using conversational AI in a dermatology patient chart audit.
- **2025-06** — Introduced Sagan, blending voice and text conversations with real HCP and patient panels, simulations and real-time analysis.
- **2024-01** — Acquired Vivisum Partners and its Brand Builder program to extend ZoomRx further into pre-launch strategy.

## Links

- Website: https://zoomrx.com/
- LinkedIn: https://www.linkedin.com/company/zoomrx/
- Twitter/X: https://twitter.com/zoomrx
- YouTube: https://www.youtube.com/@ZOOMRX
- Instagram: https://www.instagram.com/zoomrx_official/
- Facebook: https://www.facebook.com/TeamZoomRx

---

Profile page: https://yespress.io/zoomrx
Published by YesPress — https://yespress.io
Last updated: 2026-08-22